Viral hepatitis C (abbreviated as hepatitis C) is an infectious disease caused by hepatitis C virus (HCV), which is quite serious to human health. In fact, the incidence of hepatitis C in China is not low, and the trend is increasing year by year. On the other hand, compared with hepatitis B, the proportion of hepatitis C virus infection becoming chronic hepatitis, chronic hepatitis C progressing to cirrhosis and developing into liver cancer is higher, and the time required is shorter, according to the information provided by China’s “Hepatitis C Prevention and Control Guidelines”, the chronicity rate of hepatitis C virus infection is 50-80%, and after 20 years of infection, the incidence of cirrhosis in the general population is 10-15%, and the incidence of cirrhosis in middle-aged The European Hepatitis C Guidelines published in 2011 stated that 33% of patients with hepatitis C-related liver cancer may lose their lives within one year of definitive diagnosis, which shows the danger of hepatitis C to the human body. The danger of hepatitis C to the human body is evident. Most patients with hepatitis C can have mild or no symptoms for a long time, and even their liver function can be normal or only mildly abnormal, so it is easy to be ignored, but the pathological damage to the liver is still “quietly” progressing, and once the symptoms become obvious, the disease is often already in the late stages or even has progressed to cirrhosis or liver cancer. Therefore, chronic hepatitis C is called the “silent killer” by the medical profession. However, hepatitis C is a curable disease, and standardized treatment with interferon (represented by pegylated interferon, commonly known as “long-acting interferon”) plus ribavirin can result in a durable virological response in 60-80% of patients, most of whom can achieve a virological cure without relapse for a long time after discontinuation of the drug. . Timely detection and treatment is one of the keys to the best outcome. Because hepatitis C has a special transmission route of blood transmission, people with the following high-risk behaviors should be the key screening target for hepatitis C. It is especially important to emphasize that these people should go to medical institutions for hepatitis C-related screening in a timely and proactive manner even if they have no obvious symptoms (unfortunately, only about 10% of newly diagnosed hepatitis C cases in China are detected after patients go to hospitals on their own initiative). (discovered). 1.Patients who have a history of blood transfusion or blood product transfusion, especially before the mid-1990s, including whole blood, fresh or lyophilized plasma and other blood components; 2.Patients on long-term hemodialysis; 3.Patients who have donated blood at informal blood stations, especially those who have had red blood cell transfusion after single-collection plasma or other blood components; 4.Patients with intravenous drug addiction; 5.Patients with multiple Sexual partners, especially female “sex workers”; 6. Those who have undergone surgeries or other invasive examinations and treatments in informal medical institutions without sanitary conditions, such as dental treatment – tooth extraction, scaling and tattooing, ear piercing, etc.; 7. Medical personnel who have sustained accidental injuries during the treatment of hepatitis C patients. In addition, those who do not have any of the above high-risk behaviors and have unknown causes of liver function abnormalities should also be alerted to the possibility of hepatitis C. Hepatitis C-related tests should also be performed to minimize missed diagnoses and to facilitate timely and effective treatment.